Bioventus, which offers non-invasive and surgical products for treatment of musculoskeletal conditions, filed on Thursday with the SEC to raise up to $150 million in an initial public offering.
The Durham, NC-based company was founded in 2012 and booked $266 million in sales for the 12 months ended April 2, 2016. It plans to list on the Nasdaq under the symbol BIOV. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
